Literature DB >> 19386502

3D QSAR of novel estrogen-RGD peptide conjugates: getting insight into structural dependence of anti-osteoporosis activity and side effect of estrogen in ERT.

Ming Zhao1, Jiangyuan Liu, Xiaoyi Zhang, Li Peng, Chunyu Li, Shiqi Peng.   

Abstract

To explore the structural dependence of the oral potency and side effect of estrogen-RGD peptide conjugates, here six novel conjugates were prepared via introducing RGD-tetrapeptides into both 3- and 17-positions of estradiol, and introducing RGD-octapeptides into 3-position of estrone. In an ovariectomized mouse model they exhibited higher anti-osteoporosis activity and lower side effect than estrogen. For 3D QSAR analysis the anti-osteoporosis activities of nine known conjugates estrogen-RGD tetrapeptide conjugates were also provided. Using Cerius(2) module their 3D QSAR analysis was performed, four equations with high r(2) values were established, and the structural dependence of the oral potency and side effect of them was elucidated.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19386502     DOI: 10.1016/j.bmc.2009.03.057

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  4 in total

1.  Vericiguat Modulates Osteoclast Differentiation and Bone Resorption via a Balance between VASP and NF-κB Pathways.

Authors:  Kaiqiang Sun; Fanqi Kong; Feng Lin; Fudong Li; Jingchuan Sun; Changzhen Ren; Bing Zheng; Jiangang Shi
Journal:  Mediators Inflamm       Date:  2022-06-16       Impact factor: 4.529

Review 2.  Estrogen receptors alpha (ERα) and beta (ERβ): subtype-selective ligands and clinical potential.

Authors:  Ilaria Paterni; Carlotta Granchi; John A Katzenellenbogen; Filippo Minutolo
Journal:  Steroids       Date:  2014-06-24       Impact factor: 2.668

3.  Design, synthesis and evaluation of VEGF-siRNA/CRS as a novel vector for gene delivery.

Authors:  Wen Zhao; Yifan Zhang; Xueyun Jiang; Chunying Cui
Journal:  Drug Des Devel Ther       Date:  2016-11-24       Impact factor: 4.162

4.  Stachydrine prevents LPS-induced bone loss by inhibiting osteoclastogenesis via NF-κB and Akt signalling.

Authors:  Jiahong Meng; Chenhe Zhou; Wenkan Zhang; Wei Wang; Bin He; Bin Hu; Guangyao Jiang; Yangxin Wang; Jianqiao Hong; Sihao Li; Jiamin He; Shigui Yan; Weiqi Yan
Journal:  J Cell Mol Med       Date:  2019-07-21       Impact factor: 5.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.